TCGA-BH-A0C7-01B-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 92
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.550
- INTERFERON_ALPHA_RESPONSE+0.490
- MITOTIC_SPINDLE+0.460
- ESTROGEN_RESPONSE_EARLY+0.290
- INTERFERON_GAMMA_RESPONSE+0.250
- DNA_REPAIR+0.170
- MYC_TARGETS_V1+0.160
- APOPTOSIS+0.140
- ESTROGEN_RESPONSE_LATE+0.130
Top 10 suppressed
- COAGULATION-0.330
- ALLOGRAFT_REJECTION-0.320
- PANCREAS_BETA_CELLS-0.230
- IL6_JAK_STAT3_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.190
- INFLAMMATORY_RESPONSE-0.180
- MYOGENESIS-0.180
- APICAL_SURFACE-0.160
- HYPOXIA-0.130
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0DD-01A-31R-A12P-07 | — | B | 0.750 |
| 2 | TCGA-B6-A1KN-01A-11R-A13Q-07 | — | C | 0.745 |
| 3 | TCGA-E2-A10A-01A-21R-A115-07 | — | B | 0.716 |
| 4 | FC2F983B-2530-4886-B759-E2C571E2D068 | — | — | 0.704 |
| 5 | MDT-AP-3247 | Med | Medulloblastoma | 0.700 |
| 6 | TCGA-A2-A25C-01A-11R-A169-07 | — | B | 0.697 |
| 7 | SRR934757 | — | — | 0.677 |
| 8 | TCGA-CR-6493-01A-11R-1873-07 | — | — | 0.669 |
| 9 | C4C1F171-9B72-4527-9C03-39C2C00A5B6C | — | — | 0.668 |
| 10 | SRR934751 | — | — | 0.667 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.460 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |